Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2025-01-23 00:00:00 ET · period of report 2025-01-21 · accession 0000950170-25-008357 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-23 | 2025-01-21 | PHAT | Henderson Molly | CFO, CBO | S - Sale | $6.59 | -6,583 | 93.5K | -7% | -$43.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-21 | S | D | 6,583 | $6.59 | 93,546 | D | — | — | (F1) Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $6.5855 to $6.6519. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025. |